• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

ICI疗效信息门户:用于预测免疫检查点抑制剂应答者的知识库。

ICI efficacy information portal: a knowledgebase for responder prediction to immune checkpoint inhibitors.

作者信息

Chen Jiamin, Rebibo Daniel, Cao Jianquan, Mok Simon Yat-Man, Patel Neel, Tseng Po-Cheng, Zhang Zhenghao, Yip Kevin Y

机构信息

Department of Computer Science and Engineering, The Chinese University of Hong Kong, Shatin, New Territories, Hong Kong SAR.

Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, USA.

出版信息

NAR Cancer. 2023 Mar 3;5(1):zcad012. doi: 10.1093/narcan/zcad012. eCollection 2023 Mar.

DOI:10.1093/narcan/zcad012
PMID:36879684
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9984987/
Abstract

Immune checkpoint inhibitors (ICIs) have led to durable responses in cancer patients, yet their efficacy varies significantly across cancer types and patients. To stratify patients based on their potential clinical benefits, there have been substantial research efforts in identifying biomarkers and computational models that can predict the efficacy of ICIs, and it has become difficult to keep track of all of them. It is also difficult to compare findings of different studies since they involve different cancer types, ICIs, and various other details. To make it easy to access the latest information about ICI efficacy, we have developed a knowledgebase and a corresponding web-based portal (https://iciefficacy.org/). Our knowledgebase systematically records information about latest publications related to ICI efficacy, predictors proposed, and datasets used to test them. All information recorded is checked carefully by a manual curation process. The web-based portal provides functions to browse, search, filter, and sort the information. Digests of method details are provided based on the original descriptions in the publications. Evaluation results of the effectiveness of the predictors reported in the publications are summarized for quick overviews. Overall, our resource provides centralized access to the burst of information produced by the vibrant research on ICI efficacy.

摘要

免疫检查点抑制剂(ICI)已在癌症患者中产生了持久的反应,但其疗效在不同癌症类型和患者之间存在显著差异。为了根据患者的潜在临床获益进行分层,人们在识别能够预测ICI疗效的生物标志物和计算模型方面付出了大量研究努力,以至于很难追踪所有这些研究。由于不同研究涉及不同的癌症类型、ICI以及各种其他细节,因此也难以比较不同研究的结果。为了便于获取有关ICI疗效的最新信息,我们开发了一个知识库和一个相应的基于网络的门户网站(https://iciefficacy.org/)。我们的知识库系统地记录了有关与ICI疗效相关的最新出版物、提出的预测指标以及用于测试这些指标的数据集的信息。通过人工整理过程对记录的所有信息进行仔细检查。基于网络的门户网站提供了浏览、搜索、筛选和分类信息的功能。根据出版物中的原始描述提供方法细节摘要。总结了出版物中报道的预测指标有效性的评估结果,以便快速概览。总体而言,我们的资源提供了对ICI疗效活跃研究产生的大量信息的集中访问。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/12f8/9984987/057ec43be1f6/zcad012fig5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/12f8/9984987/37bb1f8cdb05/zcad012figgra1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/12f8/9984987/860899cbdd6a/zcad012fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/12f8/9984987/56b6a5407ebd/zcad012fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/12f8/9984987/0cc9ee52b47f/zcad012fig3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/12f8/9984987/e8d1fbcd8d39/zcad012fig4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/12f8/9984987/057ec43be1f6/zcad012fig5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/12f8/9984987/37bb1f8cdb05/zcad012figgra1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/12f8/9984987/860899cbdd6a/zcad012fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/12f8/9984987/56b6a5407ebd/zcad012fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/12f8/9984987/0cc9ee52b47f/zcad012fig3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/12f8/9984987/e8d1fbcd8d39/zcad012fig4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/12f8/9984987/057ec43be1f6/zcad012fig5.jpg

相似文献

1
ICI efficacy information portal: a knowledgebase for responder prediction to immune checkpoint inhibitors.ICI疗效信息门户:用于预测免疫检查点抑制剂应答者的知识库。
NAR Cancer. 2023 Mar 3;5(1):zcad012. doi: 10.1093/narcan/zcad012. eCollection 2023 Mar.
2
Multidisciplinary Educational Program to Standardize Education and Management of Immune-related Adverse Events: Review and Outcomes of a Single-institution Initiative.多学科教育计划规范免疫相关不良事件的教育和管理:单机构计划的回顾和结果。
Am J Clin Oncol. 2024 Sep 1;47(9):419-424. doi: 10.1097/COC.0000000000001112. Epub 2024 May 17.
3
A Network Comparison on Safety Profiling of Immune Checkpoint Inhibitors in Advanced Lung Cancer.免疫检查点抑制剂在晚期肺癌中的安全性特征网络比较。
Front Immunol. 2021 Dec 3;12:760737. doi: 10.3389/fimmu.2021.760737. eCollection 2021.
4
Efficacy and predictors of rechallenge with immune checkpoint inhibitors in non-small cell lung cancer.免疫检查点抑制剂在非小细胞肺癌中的再挑战疗效和预测因素。
Thorac Cancer. 2022 Feb;13(4):624-630. doi: 10.1111/1759-7714.14309. Epub 2022 Jan 6.
5
The efficacy-associated biomarkers for immune checkpoint inhibitors in gastrointestinal cancer: a literature review.胃肠道癌中免疫检查点抑制剂的疗效相关生物标志物:文献综述
J Gastrointest Oncol. 2024 Feb 29;15(1):514-528. doi: 10.21037/jgo-23-843. Epub 2024 Feb 28.
6
Transarterial Chemoembolization Combined with Tyrosine Kinase Inhibitors Plus Immune Checkpoint Inhibitors Versus Tyrosine Kinase Inhibitors Plus Immune Checkpoint Inhibitors in Unresectable Hepatocellular Carcinoma with First- or Lower-Order Portal Vein Tumor Thrombosis.经动脉化疗栓塞联合酪氨酸激酶抑制剂加免疫检查点抑制剂与酪氨酸激酶抑制剂加免疫检查点抑制剂治疗不可切除的伴有一级或低级别门静脉癌栓的肝细胞癌。
Cardiovasc Intervent Radiol. 2024 Jun;47(6):751-761. doi: 10.1007/s00270-024-03724-x. Epub 2024 Apr 26.
7
Immune checkpoint inhibitors-related thyroid dysfunction: influencing factor analysis, prediction model development, and management strategy proposal.免疫检查点抑制剂相关甲状腺功能障碍:影响因素分析、预测模型建立及管理策略建议。
Cancer Immunol Immunother. 2024 Nov 2;74(1):2. doi: 10.1007/s00262-024-03816-0.
8
Real-World Clinical and Economic Outcomes in Selected Immune-Related Adverse Events Among Patients with Cancer Receiving Immune Checkpoint Inhibitors.癌症患者接受免疫检查点抑制剂治疗的特定免疫相关不良事件的真实世界临床和经济结局。
Oncologist. 2021 Nov;26(11):e2002-e2012. doi: 10.1002/onco.13918. Epub 2021 Aug 24.
9
PCDH11X mutation as a potential biomarker for immune checkpoint therapies in lung adenocarcinoma.PCDH11X突变作为肺腺癌免疫检查点疗法的潜在生物标志物。
J Mol Med (Berl). 2024 Jul;102(7):899-912. doi: 10.1007/s00109-024-02450-8. Epub 2024 May 13.
10
Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.比较单药或联合免疫检查点抑制剂与一线含或不含贝伐珠单抗的铂类化疗方案用于晚期非小细胞肺癌患者。
Cochrane Database Syst Rev. 2021 Apr 30;4(4):CD013257. doi: 10.1002/14651858.CD013257.pub3.

引用本文的文献

1
Developing foundations for biomedical knowledgebases from literature using large language models - A systematic assessment.利用大语言模型从文献中开发生物医学知识库的基础——一项系统评估
Comput Struct Biotechnol J. 2025 Jul 24;27:3299-3306. doi: 10.1016/j.csbj.2025.07.042. eCollection 2025.
2
The current landscape of spatial biomarkers for prediction of response to immune checkpoint inhibition.用于预测免疫检查点抑制反应的空间生物标志物的当前状况。
NPJ Precis Oncol. 2024 Aug 13;8(1):178. doi: 10.1038/s41698-024-00671-1.
3
Immune-related adverse events of antibody-based biological medicines in cancer therapy.

本文引用的文献

1
TIGER: A Web Portal of Tumor Immunotherapy Gene Expression Resource.TIGER:肿瘤免疫治疗基因表达资源的网络门户。
Genomics Proteomics Bioinformatics. 2023 Apr;21(2):337-348. doi: 10.1016/j.gpb.2022.08.004. Epub 2022 Aug 29.
2
Revisiting checkpoint blockade.重新审视免疫检查点阻断疗法。
Nat Biotechnol. 2022 Jul;40(7):981. doi: 10.1038/s41587-022-01407-x.
3
Molecular correlates of clinical response and resistance to atezolizumab in combination with bevacizumab in advanced hepatocellular carcinoma.晚期肝细胞癌中阿替利珠单抗联合贝伐珠单抗治疗的临床反应和耐药的分子相关性。
癌症治疗中基于抗体的生物药物的免疫相关不良反应。
J Cell Mol Med. 2024 Jul;28(13):e18470. doi: 10.1111/jcmm.18470.
Nat Med. 2022 Aug;28(8):1599-1611. doi: 10.1038/s41591-022-01868-2. Epub 2022 Jun 23.
4
Radiomics-Based Machine Learning for Outcome Prediction in a Multicenter Phase II Study of Programmed Death-Ligand 1 Inhibition Immunotherapy for Glioblastoma.基于放射组学的机器学习在多中心 PD-L1 抑制免疫治疗胶质母细胞瘤的 II 期研究中的预后预测。
AJNR Am J Neuroradiol. 2022 May;43(5):675-681. doi: 10.3174/ajnr.A7488. Epub 2022 Apr 28.
5
Improved prediction of immune checkpoint blockade efficacy across multiple cancer types.改善多种癌症类型的免疫检查点阻断疗效预测。
Nat Biotechnol. 2022 Apr;40(4):499-506. doi: 10.1038/s41587-021-01070-8. Epub 2021 Nov 1.
6
Hallmarks of response, resistance, and toxicity to immune checkpoint blockade.免疫检查点阻断的反应、耐药和毒性的特征。
Cell. 2021 Oct 14;184(21):5309-5337. doi: 10.1016/j.cell.2021.09.020. Epub 2021 Oct 7.
7
Interpretable systems biomarkers predict response to immune-checkpoint inhibitors.可解释的系统生物标志物可预测对免疫检查点抑制剂的反应。
Patterns (N Y). 2021 Jun 30;2(8):100293. doi: 10.1016/j.patter.2021.100293. eCollection 2021 Aug 13.
8
Immu-Mela: An open resource for exploring immunotherapy-related multidimensional genomic profiles in melanoma.Immu-Mela:一个探索黑色素瘤免疫治疗相关多维基因组特征的开放资源。
J Genet Genomics. 2021 May 20;48(5):361-368. doi: 10.1016/j.jgg.2021.03.016. Epub 2021 May 14.
9
Chinese Glioma Genome Atlas (CGGA): A Comprehensive Resource with Functional Genomic Data from Chinese Glioma Patients.中国脑胶质瘤基因组图谱(CGGA):来自中国脑胶质瘤患者的功能基因组数据的综合资源。
Genomics Proteomics Bioinformatics. 2021 Feb;19(1):1-12. doi: 10.1016/j.gpb.2020.10.005. Epub 2021 Mar 2.
10
Meta-analysis of tumor- and T cell-intrinsic mechanisms of sensitization to checkpoint inhibition.肿瘤和 T 细胞内在机制对检查点抑制敏感性的荟萃分析。
Cell. 2021 Feb 4;184(3):596-614.e14. doi: 10.1016/j.cell.2021.01.002. Epub 2021 Jan 27.